Completed PHASE2 INTERVENTIONAL 2-arm NCT00052689

Bortezomib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer

A Randomized Phase II Trial of PS-341 and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma

Sponsor: National Cancer Institute (NCI)

Conditions Duct Cell Adenocarcinoma of the Pancreas Stage IV Pancreatic Cancer

Interventions bortezomib gemcitabine hydrochloride

Updated 6 times since 2017 Last updated: Oct 7, 2013 Started: Dec 31, 2002 Primary completion: Oct 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Duct Cell Adenocarcinoma of the Pancreas and Stage IV Pancreatic Cancer and is currently completed. National Cancer Institute (NCI) leads this study, which shows 6 recorded versions since 2002 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Dec 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute (NCI)

Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Rochester, United States